相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Metabolite profiling in plasma and tissues of ob/ob and db/db mice identifies novel markers of obesity and type 2 diabetes
Pieter Giesbertz et al.
DIABETOLOGIA (2015)
Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating Sirt1 to resist AGEs-induced upregulation of fibronetin and transforming growth factor-β1 in rat glomerular messangial cells
Kaipeng Huang et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2015)
PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels
A. David Marais et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Comparative studies of polydatin and resveratrol on mutual transformation and antioxidative effect in vivo
Hui-Lin Wang et al.
PHYTOMEDICINE (2015)
Resveratrol Inhibits Enterovirus 71 Replication and Pro-Inflammatory Cytokine Secretion in Rhabdosarcoma Cells through Blocking IKKs/NF-κB Signaling Pathway
Li Zhang et al.
PLOS ONE (2015)
Polydatin Restores Endothelium-Dependent Relaxation in Rat Aorta Rings Impaired by High Glucose: A Novel Insight into the PPARβ-NO Signaling Pathway
Yang Wu et al.
PLOS ONE (2015)
CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism
Bin Dong et al.
ATHEROSCLEROSIS (2014)
CNX-012-570, a direct AMPK activator provides strong glycemic and lipid control along with significant reduction in body weight; studies from both diet-induced obese mice and db/db mice models
Tharappel M. Anil et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Design and Synthesis of Truncated EGF-A Peptides that Restore LDL-R Recycling in the Presence of PCSK9 In Vitro
Christina I. Schroeder et al.
CHEMISTRY & BIOLOGY (2014)
Polydatin improves glucose and lipid metabolism in experimental diabetes through activating the Akt signaling pathway
Jie Hao et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor
Yingnan Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
Susan Kuhnast et al.
JOURNAL OF LIPID RESEARCH (2014)
An Antibody against the C-Terminal Domain of PCSK9 Lowers LDL Cholesterol Levels In Vivo
Felix Schiele et al.
JOURNAL OF MOLECULAR BIOLOGY (2014)
Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells
Mi-Hsueh Tai et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2014)
Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation
Joao Marcus Oliveira Andrade et al.
NUTRITION (2014)
Alpha-Lipoic Acid Reduces LDL-Particle Number and PCSK9 Concentrations in High-Fat Fed Obese Zucker Rats
Bradley Carrier et al.
PLOS ONE (2014)
Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture
Majambu Mbikay et al.
FEBS OPEN BIO (2014)
Polydatin, A Natural Precursor of Resveratrol, Induces β-Defensin Production and Reduces Inflammatory Response
Giampietro Ravagnan et al.
INFLAMMATION (2013)
Lack of Oncostatin M Receptor β Leads to Adipose Tissue Inflammation and Insulin Resistance by Switching Macrophage Phenotype
Tadasuke Komori et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
Bertrand Cariou et al.
NUTRITION & METABOLISM (2013)
Polydatin attenuated food allergy via store-operated calcium channels in mast cell
Bo Yang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Polydatin Attenuates Hypoxic Pulmonary Hypertension and Reverses Remodeling through Protein Kinase C Mechanisms
Qing Miao et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice
Ding Ai et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Polydatin ameliorates experimental diabetes-induced fibronectin through inhibiting the activation of NF-κB signaling pathway in rat glomerular mesangial cells
Xi Xie et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study
M. C. G. J. Brouwers et al.
ATHEROSCLEROSIS (2011)
Polydatin up-regulates clara cell secretory protein to suppress phospholipase A2 of lung induced by LPS in vivo and in vitro
Shu Shiyu et al.
BMC CELL BIOLOGY (2011)
Berberine ameliorates hyperglycemia in alloxan-induced diabetic C57BL/6 mice through activation of Akt signaling pathway
Xi Xie et al.
ENDOCRINE JOURNAL (2011)
Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients
P. Costet et al.
ATHEROSCLEROSIS (2010)
PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
Majambu Mbikay et al.
FEBS LETTERS (2010)
Effects of polydatin from Polygonum cuspidatum on lipid profile in hyperlipidemic rabbits
Wei-Wei Xing et al.
BIOMEDICINE & PHARMACOTHERAPY (2009)
Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents
Alexis Baass et al.
CLINICAL CHEMISTRY (2009)
Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation EVIDENCE FOR AN INTRACELLULAR ROUTE
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Genetic and Metabolic Determinants of Plasma PCSK9 Levels
Susan G. Lakoski et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Lipid-lowering effects of polydatin from Polygonum cuspidatum in hyperlipidemic hamsters
Jian Du et al.
PHYTOMEDICINE (2009)
Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment
Gilles Lambert et al.
CLINICAL CHEMISTRY (2008)
Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels
Gaetan Mayer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Plasma PCSK9 preferentially reduces liver LDL receptors in mice
Aldo Grefhorst et al.
JOURNAL OF LIPID RESEARCH (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
Thomas A. Lagace et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Chronic palmitate but not oleate exposure induces endoplasmic reticulum stress, which may contribute to INS-1 pancreatic β-cell apoptosis
Elizabeth Karaskov et al.
ENDOCRINOLOGY (2006)
Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression
R Dentin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Surflex: Fully automatic flexible molecular docking using a molecular similarity-based search engine
AN Jain
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
分享论文
